- Home
- CELC vs HAYW Comparison
CELC vs HAYW Comparison
Compare CELC & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- HAYW
- Stock Information
- Founded
- CELC 2011
- HAYW 1925
- Country
- CELC United States
- HAYW United States
- Employees
- CELC N/A
- HAYW N/A
- Industry
- CELC Medical Specialities
- HAYW Electronic Components
- Sector
- CELC Health Care
- HAYW Technology
- Exchange
- CELC Nasdaq
- HAYW Nasdaq
- Market Cap
- CELC 3.1B
- HAYW 3.4B
- IPO Year
- CELC 2017
- HAYW 2021
- Fundamental
- Price
- CELC $100.23
- HAYW $16.75
- Analyst Decision
- CELC Strong Buy
- HAYW Buy
- Analyst Count
- CELC 7
- HAYW 4
- Target Price
- CELC $95.29
- HAYW $18.00
- AVG Volume (30 Days)
- CELC 916.2K
- HAYW 2.0M
- Earning Date
- CELC 11-12-2025
- HAYW 10-29-2025
- Dividend Yield
- CELC N/A
- HAYW N/A
- EPS Growth
- CELC N/A
- HAYW 44.13
- EPS
- CELC N/A
- HAYW 0.62
- Revenue
- CELC N/A
- HAYW $1,099,855,000.00
- Revenue This Year
- CELC N/A
- HAYW $6.69
- Revenue Next Year
- CELC N/A
- HAYW $5.53
- P/E Ratio
- CELC N/A
- HAYW $26.73
- Revenue Growth
- CELC N/A
- HAYW 9.66
- 52 Week Low
- CELC $7.58
- HAYW $11.10
- 52 Week High
- CELC $103.06
- HAYW $17.73
- Technical
- Relative Strength Index (RSI)
- CELC 78.25
- HAYW 64.06
- Support Level
- CELC $92.10
- HAYW $14.98
- Resistance Level
- CELC $103.06
- HAYW $16.41
- Average True Range (ATR)
- CELC 5.52
- HAYW 0.44
- MACD
- CELC 0.74
- HAYW 0.07
- Stochastic Oscillator
- CELC 90.84
- HAYW 96.96
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.